Abstract:Introduction Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated. Methods The ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis. Results ERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells. Conclusions Although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process.

The Synergistic Inhibitory Effect of 5-Aza-2-deoxycytidine and Tamoxifen on Estrogen Receptor Alpha Negative Breast Cancer Cell Lines in Vitro

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

[Effect of Evn-50 on Cell Growth and Apoptosis in Tamoxifen-Resistance Human Breast Cancer Cell Line MCF-7/TAM-R].

Correlation Between Expressions of Estrogen Receptor, Thymidylate Synthase and CAF Regime Sensibility in Breast Carcinoma

ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.

ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

[Expression of ER Alpha in Chemically Induced MDA-MB-435 Cells and Its Responsiveness to Endocrine].

Lower Beclin 1 Downregulates HER2 Expression to Enhance Tamoxifen Sensitivity and Predicts a Favorable Outcome for ER Positive Breast Cancer

[Expression of ER Alpha and SMRT in Apoptosis of Breast Cancer Cells Induced by Tamoxifen].

Estrogen Receptor Α Confers Nab-paclitaxel Resistance in Breast Cancer by Promoting Mir199a-5P Maturation to Inhibit Caveolin 1 Translation

Toll-Like Receptor 9 Agonist Inhibits Er Alpha-Mediated Transactivation by Activating Nf-Kappa B in Breast Cancer Cell Lines

5-Aza-2 '-Deoxycytidine Improves The Sensitivity Of Endometrial Cancer Cells To Progesterone Therapy

Expression changes of SRC-1 in breast cancer cells and its relationship with endocirine therapy

Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms

MicroRNA‐335‐5p and ‐3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance

4-Hydroxytamoxifen Enhances Sensitivity of Estrogen Receptor Α-Positive Breast Cancer to Docetaxel in an Estrogen and ZNF423 SNP-dependent Fashion

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells

[Effect of Mitogen-Activated Protein Kinase Signal Transduction in Non-Estrogen Antagonistic Mechanism of Tamoxifen].

DNA Methyltransferase Inhibitor and Rapamycin Synergistically Modulate Cell Cycle and Mammalian Target of Rapamycin Signaling Pathway for Human Colorectal Cancer Cells

Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy.